352 related articles for article (PubMed ID: 16319109)
1. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
Ho CL; Su WC; Hsieh RK; Lin ZZ; Chao TY
Jpn J Clin Oncol; 2010 Apr; 40(4):294-301. PubMed ID: 20026457
[TBL] [Abstract][Full Text] [Related]
4. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
5. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
[TBL] [Abstract][Full Text] [Related]
6. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
[TBL] [Abstract][Full Text] [Related]
8. [A randomized cross-over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP-based chemotherapy for gynecologic cancer].
Wataba K; Sagae S; Fukunaka N; Sugimura M; Akutagawa N; Hayashi T; Yamana K; Nakamura T; Terasawa K; Mizumoto H; Kitajima Y; Kudo R
Gan To Kagaku Ryoho; 1997 Apr; 24(6):691-7. PubMed ID: 9126306
[TBL] [Abstract][Full Text] [Related]
9. [Preventive effects of ramosetron and granisetron in prevention of gastrointestinal reaction associated with chemotherapeutic agents: a comparative study].
Zhang JD; Liu YP; Teng YE; Shi J
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2058-60. PubMed ID: 14703416
[TBL] [Abstract][Full Text] [Related]
10. Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia.
Feng F; Zhang P; He Y; Li Y; Zhou M; Chen G; Li L
Chin Med Sci J; 2002 Sep; 17(3):168-72. PubMed ID: 12901541
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint?
Koizumi W; Tanabe S; Nagaba S; Higuchi K; Nakayama N; Saigenji K; Nonaka M; Yago K
Chemotherapy; 2003 Dec; 49(6):316-23. PubMed ID: 14671433
[TBL] [Abstract][Full Text] [Related]
12. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
13. [Optimal timing of granisetron administration for the prevention of carboplatin-induced acute emesis].
Yamauchi H; Ishikawa H; Suzuki S; Nagaji M; Fujiwara K; Kohno I
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2217-21. PubMed ID: 10635307
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
[TBL] [Abstract][Full Text] [Related]
15. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Shi Y; He X; Yang S; Ai B; Zhang C; Huang D; Dong M; Liu P; Zhou S; Han X
Chemotherapy; 2007; 53(1):44-50. PubMed ID: 17202811
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of combination with granisetron and methylprednisolone for nausea, vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia--a randomized comparative trial between granisetron alone and granisetron plus methylprednisolone].
Ono K; Uchida I; Uno N; Ohno E; Hirota K; Nakayama T; Ohtuka E; Saburi Y; Kikuchi H; Nasu M
Gan To Kagaku Ryoho; 1999 May; 26(6):821-8. PubMed ID: 10410152
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
18. [A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis--outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group].
Ozono S; Okajima E; Hirao YK; Natsume O; Kaneko Y; Ohara S; Tabata S; Watanabe S; Aoyama H; Sasaki K; Matsuki H; Takashima K; Maruyama Y; Yoshikawa M; Yamada K; Momose H; Hiramatsu T; Hayashi Y; Babaya K; Shiomi T
Gan To Kagaku Ryoho; 1997 Feb; 24(3):349-56. PubMed ID: 9051139
[TBL] [Abstract][Full Text] [Related]
19. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
